TDP-43 inclusion is pathogenic hallmark in ALSFTLD-TDP,found in brain of  57 Alzheimer’s disease (AD) patients, who have more severe disease progression. We developed the first antibody with USTW patents recognizing misfolded TDP-43 oligomers. Mice study showed i.v. the antibody neutralizes TDP-43 toxicity in brain. The antibody has great therapeutic potential for ALS/FTLD/AD.

In 2014, we discovered full-length TDP-43 forms oligomerdeveloped specific antibody (TDP-O) against it (Nature Communications). The oligomers were shown in brains of FTLD-TDP, ALS,AD patients. Our animal studies showed i.v. injection of TDP-O antibody neutralizes TDP-43 toxicityimproves motormemory function in diseased mice model. The antibody has great therapeutic potential.

This technology is about anti-TDP-43 oligomer antibody (US patent). TDP-43 inclusions were found in ALS, FTLD-TDP,50 Alzheimer’s disease (AD) patients. In the mice model, i.v. injection the antibody significantly improves the motormemory function. Anti-Aβ antibody, Biogen, showed good result in clinical trial 3, therefore, antibody against other aggregates is the next blockbuster.